Literature DB >> 29059002

Deactivation of cisplatin-resistant human lung/ovary cancer cells with pyropheophorbide-α methyl ester-photodynamic therapy.

Guanhua Qian1, Li Wang1, Xueling Zheng1, Tinghe Yu1.   

Abstract

The aim of this study was to determine whether photodynamic therapy (PDT) alone or combined with cisplatin (DDP), can deactivate cisplatin-resistant cancer cells. Human cancer cell lines A549 and SKOV3, and chemoresistant sublines A549/DDP and SKOV3/DDP, were subjected to PDT, DDP, or PDT combined with DDP. Cell viability and apoptosis were analyzed, and then intracellular reactive oxygen species (ROS) and proteins related to apoptosis were determined. PDT caused cell death, and PDT combined with DDP led to the highest percentage of dead cells in 4 cell lines; similar results were detected in ROS; a quantification evaluation manifested that the combined effect was addition. DDP increased the percentage of apoptotic cells, and the ROS level in A549 and SKOV3 cells, which was not observed in A549/DDP and SKOV3/DDP cells. Western blot revealed an increase of caspase 3 and Bax, and a decrease of Bcl-2, demonstrating the occurrence of apoptosis. The data suggest that PDT can efficiently deactivate resistant cells and enhance the action of DDP against resistant cancer cells.

Entities:  

Keywords:  cisplatin resistance; photodynamic therapy; pyropheophorbide-α methyl ester; reactive oxygen species

Mesh:

Substances:

Year:  2017        PMID: 29059002      PMCID: PMC5718780          DOI: 10.1080/15384047.2017.1385683

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  17 in total

1.  Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.

Authors:  Tinghe Yu; Yan Yang; Jiao Zhang; Haining He; Xueyi Ren
Journal:  Eur J Pharm Biopharm       Date:  2015-02-07       Impact factor: 5.571

Review 2.  The potential of photodynamic therapy (PDT)-Experimental investigations and clinical use.

Authors:  Anna Oniszczuk; Karolina A Wojtunik-Kulesza; Tomasz Oniszczuk; Kamila Kasprzak
Journal:  Biomed Pharmacother       Date:  2016-08-10       Impact factor: 6.529

Review 3.  Pharmacokinetic profiles of cancer sonochemotherapy.

Authors:  Ying Zhang; Jinyan Li; Tinghe Yu
Journal:  Expert Opin Drug Deliv       Date:  2016-09-08       Impact factor: 6.648

4.  Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin.

Authors:  Wenxia Hu; Pule Jin; Wei Liu
Journal:  Cell Physiol Biochem       Date:  2016-03-17

5.  A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells.

Authors:  Xi Han; Shuai Zhen; Zhongxue Ye; Jiaojiao Lu; Lijie Wang; Pan Li; Jie Li; Xia Zheng; Huijin Li; Wei Chen; Xu Li; Le Zhao
Journal:  Cell Physiol Biochem       Date:  2017-02-21

6.  MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1.

Authors:  Peng Li; Xiao Yang; Yidong Cheng; Xiaolei Zhang; Chengdi Yang; Xiaheng Deng; Pengchao Li; Jun Tao; Haiwei Yang; Jifu Wei; Jingyuan Tang; Wenbo Yuan; Qiang Lu; Xiaoting Xu; Min Gu
Journal:  Cell Physiol Biochem       Date:  2017-02-20

Review 7.  Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT.

Authors:  C A Robertson; D Hawkins Evans; H Abrahamse
Journal:  J Photochem Photobiol B       Date:  2009-04-11       Impact factor: 6.252

Review 8.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

9.  Induction of cell death by pyropheophorbide-α methyl ester-mediated photodynamic therapy in lung cancer A549 cells.

Authors:  Ping-Hua Tu; Wen-Jun Huang; Zhan-Ling Wu; Qing-Zhen Peng; Zhi-Bin Xie; Ji Bao; Ming-Hua Zhong
Journal:  Cancer Med       Date:  2017-02-09       Impact factor: 4.452

Review 10.  Systems biology of cisplatin resistance: past, present and future.

Authors:  L Galluzzi; I Vitale; J Michels; C Brenner; G Szabadkai; A Harel-Bellan; M Castedo; G Kroemer
Journal:  Cell Death Dis       Date:  2014-05-29       Impact factor: 8.469

View more
  2 in total

Review 1.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

Review 2.  Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies.

Authors:  Sepideh Mirzaei; Kiavash Hushmandi; Amirhossein Zabolian; Hossein Saleki; Seyed Mohammad Reza Torabi; Adnan Ranjbar; SeyedHesam SeyedSaleh; Seyed Omid Sharifzadeh; Haroon Khan; Milad Ashrafizadeh; Ali Zarrabi; Kwang-Seok Ahn
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.